Adverse Effect Profile and Effectiveness of Sodium Glucose Co-transporter 2 Inhibitors (SGLT2i) - A Prospective Real-world Setting Study.

Recent posthoc analysis of canagliflozin also showed a trend toward higher rate of UTI in hot climate countries when compared with other areas (9.5% vs 4.6% at 26 weeks of placebo-controlled period, 22.3% v 7.4% at 104 weeks of active controlled period with canagliflozin 100 mg).[ 22 ] Second most common complaint which we noticed was feeling of weakness and lethargy and importantly this led to discontinuation of drug in 3.3% of patients.

also in 53,322 other papers